BofA raised the firm’s price target on AbbVie (ABBV) to $204 from $200 and keeps a Neutral rating on the shares following what the firm calls a “decent quarter” and “slight guidance raise.” Revenue and EPS if excluding IPR&D guidance were raised by about 1% and the firm’s estimates were, and still are, above this as “the company frequently guides conservatively,” the analyst added.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie price target lowered to $205 from $230 at HSBC
- AbbVie: Strong Financial Performance and Growth Prospects Drive Positive Analyst Outlook
- AbbVie price target raised to $250 from $241 at Morgan Stanley
- AbbVie Stock (ABBV) Up 8% on the Week as Company Soars Past Q1 Expectations
- AbbVie Reports Strong Q1 2025 Financial Results